Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.

@article{Miernyk2009ImmunogenicityAR,
  title={Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.},
  author={Karen M Miernyk and J. Corey Butler and Lisa R. Bulkow and Rosalyn J. Singleton and Thomas W. Hennessy and Catherine M. Dentinger and Helen V Peters and Barbara Knutsen and Jack Hickel and Alan J. Parkinson},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2009},
  volume={49 2},
  pages={241-8}
}
BACKGROUND Vaccination with conjugate vaccines stimulates T cell-dependent immunity, whereas vaccination with polysaccharide vaccines does not. Thus, vaccination with the 7-valent pneumococcal conjugate vaccine (PCV7) followed by the 23-valent pneumococcal polysaccharide vaccine (PPV23) may offer better protection against invasive pneumococcal disease for older adults than does vaccination with PPV23 alone, which is what is currently recommended. METHODS Alaska Native adults 55-70 years of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2011
View 6 Excerpts
Highly Influenced

Bacterial Respiratory Infections Complicating Human Immunodeficiency Virus.

Seminars in respiratory and critical care medicine • 2016
View 2 Excerpts

Theory and strategy for Pneumococcal vaccines in the elderly

Human vaccines & immunotherapeutics • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…